[Clinical and biochemical aspects of flixotide administration in patients with moderate bronchial asthma].
OBJECTIVE
To compare clinical, device and biochemical aspects of monotherapy with flixotide vs combination of flixotide with serevent in patients with moderate bronchial asthma (MBA).


METHODS
18 patients with MBA received flixotide and 18 MBA patients flixotide plus serevent for two weeks of lead-in and eight weeks of basic treatment. A special study was made of neutrophils which were examined for activity of LPO-antioxidants and phospholipid spectrum of membranes.


RESULTS
There were similar changes in function of the system LPO-antioxidants and lipid structure in neutrophilic membranes of moderate BA patients of both the groups.


CONCLUSIONS
Clinicobiochemical efficacy of mean doses of a new topic inhalation glucocorticoid flixotide alone or in combination with prolonged beta 2-adrenostimulator serevent is demonstrated. There were positive trends in metabolic processes in neurophilic membrane. Use of flixotide in combination with serevent is clinically preferable.
Medvedeva
I V
IV
Lapik
S V
SV
Gur'eva
S A
SA
Savina
I A
IA
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000730:Androstadienes / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002374:Catalase / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D005980:Glutathione Reductase / Q000097:blood; D006801:Humans; D015227:Lipid Peroxidation; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D010743:Phospholipids / Q000097:blood; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects; D000068299:Salmeterol Xinafoate; D012545:Schiff Bases / Q000097:blood; D013482:Superoxide Dismutase / Q000097:blood; D024502:alpha-Tocopherol / Q000097:blood
D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D010743:Phospholipids; D018343:Receptors, Adrenergic, beta-2; D012545:Schiff Bases; D008315:Malondialdehyde; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D002374:Catalase; D013482:Superoxide Dismutase; D005980:Glutathione Reductase; D024502:alpha-Tocopherol; D000420:Albuterol